AIDS Response

A six-monthly HIV prevention injection containing lenacapavir has been confirmed effective in two pivotal studies. The first study, PURPOSE 1, showed no HIV infections among two-thousand-134 participants, while the second, PURPOSE 2, reported two infections among two-thousand-179 participants. This translates to a 96-percent reduction in HIV infections compared to background incidence. Gilead Sciences plans to file for regulatory approval to market lenacapavir for prevention. Separately, during a press briefing on Monday, the U.S. Department […]